New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading ...

Cassava Sciences rebrands to Filana Therapeutics (FLNA) on March 11, 2026, focusing on filamin A CNS therapies for TSC epilepsy—get the latest update.

Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy Further fortified our strategic capabilities with the appointment of Dawn ...

The appointment of Dr. Jack Moore as Senior Vice President, Clinical Development brings extensive experience in CNS drug development, which could enhance the company’s initiatives for simufilam and ...

In an unusual and unexpected twist, the U.S. Department of Justice (DOJ) filed an “unopposed motion … to dismiss with prejudice” a June 2024 criminal indictment against a Cassava Sciences advisor ...

Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials. Overview: Cassava Sciences’ simufilam is a novel, small molecule drug ...

Cassava Sciences ( (SAVA)) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors. Cassava Sciences, Inc. is a biotechnology company ...

Cassava Sciences is a clinical-stage biotechnology firm developing novel treatments for central nervous system (CNS) diseases. Its main asset, simufilam, is a proprietary oral drug that initially ...

The MarketWatch News Department was not involved in the creation of this content. -- Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of ...